(RTTNews) - On Thursday, Eli Lilly and Company (LLY) reported post-hoc analyses from the Phase 3 ATTAIN-1 trial showing that Foundayo was associated with significant reductions in predicted 10-year risks of type 2 diabetes and cardiovascular disease in adults with obesity or over
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.